In conclusion, these observations indicate that Comp.11 treatment is able to reverse the CtBP1/BARS-mediated transcriptional repression of PTEN, p53, BRCA1 and BRIP1 genes, activating apoptosis and reducing melanoma initiation. Here, TP53 is linked to melanoma.